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Diseases of the musculoskeletal system are a major cause of loss of use and retirement 
in sport horses. The use of bone marrow-derived mesenchymal stem cells (BMDMSCs) 
for healing of traumatized tissue has gained substantial favor in clinical settings and can 
assist healing and tissue regeneration in orthopedic injuries. There are two common sites 
of harvest of BMDMSCs, the sternum and the ilium. Our objective was to determine if 
any differences exist in BMDMSCs acquired from the sternum and the ilium. We com-
pared the two harvest sites in their propensity to undergo multilineage differentiation, 
differences in cell surface markers, or gene transduction efficiencies. BMDMSCs were 
isolated and culture-expanded from 5 ml aspirates of bone marrow from sternum and 
ilium. The cells were then plated and cultured with appropriate differentiation medium 
to result in multi-lineage differentiation and cell characteristics were compared between 
sternal and ilial samples. Cell surface antibody expression of CD11a/18, CD34, CD44, 
and CD90 were evaluated using flow cytometry, and gene transduction efficiencies 
were evaluated using GFP scAAV. There were no statistically significant differences in 
cell characteristics between MSCs cultured from the sternum and the ilium under any 
circumstances.
Keywords: stem cells, horse, regeneration, orthopedic, tendon, gene therapy
inTrODUcTiOn
Diseases of the musculoskeletal system are a major cause of retirement and euthanasia in horses (1). 
Currently, a wide range of treatment modalities exist and are used depending on the severity of lame-
ness. Stem cells are the topic of much discussion due to their healing potential in orthopedic injuries 
(2, 3). Mesenchymal stem cells (MSCs) are thought to increase healing by promoting regeneration 
of tissues, as MSCs are multi-potent in vitro (4–6). Autologous MSCs are commonly acquired from 
bone marrow aspirates and those bone marrow-derived mesenchymal stem cells (BMDMSCs) have 
been shown to possess multi-lineage potential in vitro (3, 5, 7). A recent study suggests that sources 
of BMDMSCs affect their propensity to differentiate and migrate in various tissue types (6).
It has become common practice to harvest bone marrow aspirates in the equine when stem cell 
therapy is pursued. There are two sites of marrow aspiration in the horse: the sternum and wing of 
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the ilium. Currently, the harvest location is completely dependent 
on clinician preference as there is limited research comparing the 
cell properties of BMDMSCs from each site. Previous studies 
have compared growth characteristics, in which BMDMSCs from 
the sternum and ilium draws had similar growth rates (8). Draw 
volumes in relationship to differentiation potential has also been 
investigated, revealing the majority of BMDMSCs are obtained 
in the first 5 ml of marrow aspirates (9). A recent study indicated 
cells acquired from the equine sternum were significantly more 
proliferative than those from the ilium in middle-aged horses 
(10). Another paper examining overdraw aspirates of bone mar-
row reported that BMDMSCs from iliac samples proliferate faster 
than sternum cells (9). A standard has been put forward, which 
recommends equine MSCs be graded according to a quality 
standard similar to one in human medicine (11). The standard 
includes trilineage differentiation potential as well as cell surface 
marker expression. There have been several studies attempting 
to determine a specific monoclonal antibody representative of 
equine MSCs (12, 13), and to date, there are several cell surface 
markers thought to indicate multipotency of MSCs.
Mesenchymal stem cells are considered a treatment of choice 
for tendon defects (2, 14–16) as they allow for appropriate differ-
entiation of fiber matrices and appear to reduce the incidence of 
re-injury. Evaluation of tenogenesis in vitro has proven challeng-
ing (17, 18) but has recently been successful (6, 19) with the addi-
tion of bone morphogenic protein 12 (BMP-12) in monolayer. 
It was therefore an objective of this study to evaluate tenogenic 
capacity in vitro in addition to classic tri-lineage evaluation.
The therapeutic potential of MSCs is also known to be 
enhanced through genetic modification (20, 21). Gene therapy 
offers a unique opportunity to influence the growth factors sur-
rounding orthopedic defects, and is of much focus in current 
research. This study also examined genetic transduction potential 
of BMDMSCs acquired from sternum and ilium, to determine the 
differences in efficiencies critical to future endeavors. Therefore, 
the objective of this study was to compare the trilineage potential 
of BMDMSCs harvested from sternum and ilium and further to 
examine tenogenesis, cell surface markers, and gene therapeutic 
potential. Our hypothesis was that there would be minimal differ-
ences between aspiration locations when the cell characteristics 
of 5 ml samples were compared in young (2–5 years old) horses.
MaTerials anD MeThODs
Bone marrow aspirates from sternum and ilium were acquired 
from nine horses aged between 2 and 5  years. Red blood cells 
were removed with centrifugation and cultured overnight in 
supplemented DMEM (Invitrogen, Grand Island, NY, USA) 
[10% FBS (Fisher, El Paso, TX, USA), 10,000  U/ml Pencillin–
Streptomyocin–Amphotoricn B (Invitrogen, Grand Island, NY, 
USA) (PSA), 1N HEPES (Invitrogen, Grand Island, NY, USA)]. 
Media was changed after 24  h, and colonies were observed 
after 7–10 days in culture. Once colonies were established, cells 
were cultured in low glucose αMEM (Invitrogen, Grand Island, 
NY, USA) supplemented with 10%FBS, 10,000  U/ml PSA, 1N 
HEPES, and 2  ng/ml FGF (R&D Systems, Minneapolis, MN, 
USA). Cells were passaged three times in monolayer before being 
cryogenically preserved for evaluation. Passage three cells were 
recovered overnight and plated to a confluency of 50,000 cells/
cm2 for differentiation assessments unless otherwise indicated.
adipogenesis
Cells from donors (n = 9) were treated with DMEM containing 
10% fetal bovine serum (FBS), 10,000  U/ml PSA, 1N HEPES, 
0.5 mM isobutyl-methylxanthine (Sigma-Aldrich, St. Louis, MO, 
USA), 1  μM dexamethasone (Sigma-Aldrich, St. Louis, MO, 
USA), 10 μM insulin (Sigma-Aldrich, St. Louis, MO, USA), and 
200  μM indomethacin (Sigma-Aldrich, St. Louis, MO, USA). 
Negative controls were grown in DMEM with 10% FBS, 10,000 U/
ml PSA, and 1N HEPES. Cells were maintained for 14 days and 
then stained with Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) 
to detect lipid deposits.
Osteogenesis
Cells from donors (n = 9) were treated with DMEM containing 
10% FBS, 10,000 U/ml PSA, 1N HEPES, 0.1 μM dexamethasone, 
5  mM beta-glycerol phosphate (Sigma-Aldrich, St. Louis, MO, 
USA), and 170 μM ascorbic acid (Sigma-Aldrich, St. Louis, MO, 
USA). Negative controls were grown in DMEM containing 10% 
FBS, 10,000 U/ml PSA, and 1N HEPES. Cells were maintained 
for 14 days and then stained with alizarin red and alkaline phos-
phatase to detect mineralization changes consistent with bone 
development. Alkaline phosphatase production was quantified 
from cell lysates with an ELISA kit (Anaspec). Cell lysates were 
also evaluated for gene expression of alkaline phosphatase (Alk 
Phos), collagen type III (Col 3), osteocalcin, osteonectin, and 
runt-related transcription factor 2 (RUNX2) as described below.
chondrogenesis
Cells from donors (n = 9) were suspended in a 2% low melting 
agarose gel (Invitrogen, Grand Island, NY, USA) at a concentration 
of 10 million cells/ml. Cell wells were cultured in supplemented 
DMEM containing 1% ITS+ (Sigma-Aldrich, St. Louis, MO, 
USA), non-essential amino acids (Sigma-Aldrich, St. Louis, MO, 
USA), 100  nM dexamethasone, 10  µM ascorbate-2-phosphate 
(Sigma-Aldrich, St. Louis, MO, USA), and 5 ng/ml TGFβ (R&D 
Systems, Minneapolis, MN, USA) for 14 days. Toluidine blue was 
used to detect extracellular matrix in gel samples, which were 
also papain digested for total glycosaminoglycan (GAG) using 
a DMMB assay.
Tenogenesis
Cells from donors (n = 9) were cultured in supplemented DMEM 
containing 50 ng/ml of recombinant BMP12 (Sigma-Aldrich, St. 
Louis, MO, USA) (rBMP12), 10,000 U/ml PSA, and 1N HEPES 
for 14 and 21  days. Negative samples were cultured in media 
containing all supplements listed above except rBMP12. Samples 
were evaluated for gene expression of collagen type I (COL I), 
scleraxis, and tenascin as described below.
cell surface Markers
Cells from donors (n = 9) were plated to a confluency of 35,000 
cells/cm2 and cultured to 80% confluency in DMEM with 10% FBS, 
10,000 U/ml PSA, and 1N HEPES. Accumax (Sigma-Aldrich, St. 
Primer sequences
I Col1 Forward – ATTTCCGTGCCTGGCCCCATG,  
Reverse – GCCTTGGAAACCTTGGGGAC
II Scleraxis Forward – CTGAGCTGACCCCAGCACTT, 
Reverse – CCAGAAGAAAACCCAGGTAGGA
III Tenscin Forward – CCGGAATATGAATAAAGAAGACGAA, 
Reverse – CGTACTCTTGCCCAGGAGCTA
IV ALP Forward – AAGCACTCTCACTACATCTGGAACCGG, 
Reverse – GCTCAAAGAGACCCAAGAGGTAATCC
V Col 3 Forward – GGTCAGTCCTATGCGGATAGAGA, 
Reverse – CAGAGAACAGATCCTGAGTCACAGA
VI OCN Forward – AGAGGTGCAGCCTTCGTGTCCA, 
Reverse – GCTCCCAGCCAATGATCCAGGTA
VII OSTN Forward – CCCCCGGCAATTTCATG, 
Reverse – AAGCGGTTCCAGTGCTTGAT
VII RUNX2 Forward – GGCGCATTTCAGATGATGACACTG, 
Reverse – AGCGGCTCTCAGTGAGGGATGA
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Louis, MO, USA) was used to remove cells from monolayer, and 
counts were determined using a hemacytometer. Cells were incu-
bated for 45 min at room temperature with primary antibodies for 
CD11a/18 (AbD Serotec, Raleigh, NC, USA), CD34 (Neuromics, 
Edina, MN, USA), CD44 (AbD Serotec, Raleigh, NC, USA), and 
CD90 (Veterinary Medical Research and Development, Pullman, 
WA, USA) at a concentration of 2.5 × 105 cells/ml. Samples were 
rinsed with PBS and placed in a secondary IgG, FITC antibody 
for 45 min at room temperature. Propidium iodide was used to 
determine the gating region of cells undergoing active growth (i.e., 
S2/G2/M) as described by Radcliffe et al. (12). Flow cytometry 
was used to determine the amount of fluorescence for each iliac 
and sternal MSC sample. CD73 and CD105 marker expressions 
were determined with rtPCR (data not shown).
rtPcr
RNA was extracted from samples using an RNeasy kit (Qiagen, 
Valencia, CA, USA). RNA was reverse transcribed into cDNA as 
per manufacturer’s instructions (Invitrogen, Grand Island, NY, 
USA). Tenogenic samples were evaluated at D14 and D21 for gene 
expression of Col II, scleraxisII, and tenascinIII. Osteogenic sam-
ples were evaluated for gene expression of Alkaline PhosphataseIV 
(Alk Phos), collagen type3V (Col III), osteocalcinVI, osteonectinVII 
and runt-related transcription factor 2VIII (RUNX2). All samples 
were normalized to an 18S housekeeping gene and were expressed 
relative to the non-treated control for each sample site.
statistical analysis
Paired t-tests were performed on all quantifiable assays. 
Significance was determined when p was ≤0.05.
This study was carried out in accordance with the recommen-
dations of The Institutional Animal Care and Use Committee. 
The protocol was approved by the Colorado State University 
Institutional Animal Care and Use Committee.
resUlTs
After induction of all cell lineages, morphological changes were 
noted in cells from both equine sternum and ilium (Figure 1). 
Adipogenic cells became less fibroblastic and Oil Red O stain-
ing resulted in dark red lipid staining in which the treated cells 
produced higher percentages of fatty aggregates, and the negative 
controls maintained their fibroblastic appearance. Osteogenic 
cells became cuboidal in shape, and nodules became apparent. 
Alkaline phosphatase and Alizarin Red stains both highlighted 
morphological changes associated with osteogenic differentia-
tion. Chondrogenic cultures became less friable than the negative 
controls when sliced for staining. Toluidine blue staining allowed 
us to confirm chondrogenic changes as GAG would stain blue 
when viewed under the microscope. No subjective differences 
between iliac and sternal samples were observed.
Quantifiable osteogenic characteristics of cells were not found 
to be different (Figure 2) including alkaline phosphatase levels 
(p = 0.31) and the gene expression of Alk Phos (p = 0.46), Col III 
(p = 0.27), Osteocalcin (p = 0.21), Osteonectin (p = 0.44), and 
RUNX2 (p = 0.86).
Glycosaminoglycan content in chondrogenic cultures was 
normalized to DNA and was not found to be different between 
aspiration locations (p =  0.14) (Figure 3). Cell surface marker 
antigen expression of CD11a/18 (p =  0.07), CD34 (p =  0.34), 
CD44 (p = 0.72) and CD90 (p = 0.95) was not significantly dif-
ferent between iliac and sternal cells (Figure 4).
Mesenchymal stem cells from sternum and ilium cultured 
to become tenogenic were not found to be different in gene 
expression for Col I (p = 0.18), scleraxis (p = 0.08), and tenascin 
(p = 0.59) (Figure 5). The differences between sternum and ilium 
in scleraxis expression were not significant (p = 0.08).
Gene transduction efficiencies of MSCs between sternum and 
ilium using scAAV2GFP were also not found to be statistically 
significantly different (p = 0.42) (Figure 6). Cell morphology was 
similar post-gene modification and fluorescence as measured by 
flow cytometry was not different between sites.
DiscUssiOn
Equine MSCs in vitro are well known to expand and differentiate 
into multiple cell lineages. The objective of the present study was 
to compare cell characteristics of MSCs acquired from bone mar-
row aspirates from equine sternum and ilium.
First, we observed that both cell populations adhere to plastic 
tissue culture surfaces and will expand. Previous literature is 
inconsistent with regard to growth rates of BMDMSCs derived 
from sternum and ilium, with reports indicating that there are 
gene Transduction
Transduction efficiencies were determined for iliac and sternal 
cells using a scAAV, serotype 2, expressing GFP (green fluorescent 
protein). Cells were plated at 60,000 cells/cm2 in supplemented 
DMEM and cultured overnight. GFP–scAAVV2 was used to 
transduce cells at a concentration of 8,000 viral particles/cells (vp/
cell) for 3  h in non-supplemented DMEM. Fresh DMEM with 
10% FBS, 10,000 U/ml PSA, and 1N HEPES was then added to 
the cells, and they were cultured for 4 days. Cells were removed 
from culture using Accumax and evaluated with flow cytometry.
FigUre 1 | Mscs in culture stained to confirm morphologic change. (a) Oil Red O to detect lipid deposits in adipogenic culture. (B) Alizarin Red to detect 
mineralization and (c) Alkaline Phosphatase to detect enzymatic activity in osteogenic culture. (D) Toluidine blue to detect extracellular matrix in agarose 
chondrogenic culture. All four stains confirm morphologic change of MSCs in vitro.
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no differences (8), that ilium proliferate faster in younger horses 
(9) and that sternal cells proliferate significantly faster in  vitro 
than ilial cells in middle-aged horses (10). Our study began with 
subjective differences in multi-lineage cellular morphology. There 
were no observed differences in BMDMSCs treated from sternum 
and ilium. Thus, the ability of these cells to become adipogenic, 
chondrogenic and osteogenic are consistent with prior studies 
examining differentiation capacities in  vitro for BMDMSCs 
acquired from either the sternum or from ilium (4, 22, 23).
With respect to osteogenic differentiation, quantification was 
not found to be significantly different across aspiration locations 
when evaluating total alkaline phosphatase production and 
relative gene expression of osteogenic genes Alk Phos, Col III, 
Osteocalcin, Osteonectin, and RUNX2 (Figure 2). Multiple stud-
ies have examined BMDMSC propensity to become bone in vitro 
(22, 23) but few have quantified differences in cells cultured from 
sternum and ilium (9). Our osteogenic quantification assays con-
firm the findings of Kisiday et al. in that both aspiration locations 
produce MSCs capable of similar osteogenic potential (9).
Chondrogenic potential of MSCs cultured from sternum and 
ilium was quantified using total GAG production normalized 
to DNA. Our results indicate no statistically significant differ-
ence in cells cultured from 5 ml marrow aspirates from equine 
sternum and ilium (Figure  3). We also found no difference in 
aggrecan and Col II expression in MSCs cultured from sternum 
and ilium (data not shown). Prior studies have used Col II as 
a reliable marker for chondrogenic differentiation in vitro (24), 
therefore our results confirm chondrogenic change occurred and 
was no difference in cells acquired from sternum and ilium. The 
similar chondrogenic propensity of sternal or ilial MSCs in this 
study differ from Kisiday et al. in which aspirates from the ilium 
were found to produce 29% more GAG in vitro when MSCs were 
placed in agarose (9). In that study, both 5 and 50 ml aspirates 
were compared between sternum and ilium and while no differ-
ences existed in small and large volume draws location effect of 
ilium influenced measured GAG levels.
Flow cytometry analysis revealed that MSCs from both ster-
num and ilium aspirates expressed CD90 and CD44 and lacked 
expression of CD11a/CD18 and CD34 (Figure  4). CD44 is an 
equine specific antibody and has been associated with a variety 
of cell types including lymphocytes, monocytes, granulocytes, 
erythrocytes, and fibroblasts (12, 25). CD90 is produced against 
canine specifically but cross reacts to equine antibodies and is also 
noted for its hematopoietic stem cell subsets including neurons, 
fibroblasts, and stromal cells (12, 26). CD11a/CD18 in human 
medicine has been associated with monocyte migration and adhe-
sion of leukocytes (27, 28). Finally, CD34 has been associated with 
neurons and related lesions in humans (12, 29, 30) and hemat-
opoiesis and platelet formation in human  progenitor cells (30).
There have been multiple markers investigated for stemness 
(11–13) as there is not a specific monoclonal antibody currently 
used to determine multi-lineage potential in the equine as there 
have been in humans. One of the major difficulties in equine 
MSC research is the low number of specific monoclonal antibod-
ies available due to the fact that the human specific monoclonal 
antibodies do not cross react with the equine species (12, 31, 32). 
FigUre 3 | chondrogenic differentiation of Mscs from sternum and 
ilium (n = 9). Quantifiable GAG produced in in vitro culture normalized to 
DNA of cells was not found to be statistically different between ilium 
(5.721 μg GAG/μgDNA ± ST error 1.26) and sternum (11.43 μg 
GAG/μgDNA ± ST error 2.64).
FigUre 2 | Osteogenic differentiation of Mscs from sternum and 
ilium (n = 9). (a) Quantifiable alkaline phosphatase produced in vitro culture 
was not found to be significantly different between sternum (1115.9 ng/
ml ± ST error 100.38) and ilium samples (586.5 ng/ml ± ST error 105.8). (B) 
Expression of genes associated with osteogenic change were not found to 
be statistically significant across treatment groups. Alk Phos expression of 
ilium (3.01 ± ST error 1.87) and sternum (8.77 ± ST error 1.08). Col III 
expression of ilium (0.30 ± ST error 0.04) and sternum (1.77 ± ST error 0.39). 
Osteocalcin expression of ilium (3.75 ± ST error 2.10) and sternum 
(0.67 ± ST error 0.205). Osteonectin expression of ilium (2.87 ± ST error 
1.84) and sternum (8.04 ± ST error 5.73). RUNX2 expression of ilium 
(0.70 ± ST error 0.45) and sternum (0.59 ± ST error 0.34).
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As bone marrow aspirate mononuclear cells become established 
rather than freshly isolated, they tend to have a more uniform 
positive expression of CD44 and CD29 (12, 31). Furthermore, 
established MSC cultures tended to increase in CD90 expression 
of intensity of fluorescence (12, 31). MSCs in culture have also 
been found to have decreased expression of CD11a/CD18 and 
CD45RB over time (12). The general consensus is that there is 
not a single monoclonal antibody currently that indicates equine 
MSC quality, but rather a collection that help to establish multi-
potency (12, 31, 32).
Our results are consistent with previous studies, suggesting 
that as MSC cultures become more homogeneous the population 
of cells decreases expression of CD11/18, CD34, and CD45 while 
increasing expression of CD44, CD90, CD117, and CD13 (12, 13, 
31). The present study focused on positive expression of CD44 
and CD90 with decreased expression of CD11/18 and CD34 and 
found no statistically significant difference in MSCs acquired 
from equine sternum or ilium.
A previous study also comparing 5  ml samples from ilium 
and sternum revealed no statistical differences in nucleated cell 
counts and growth rates in young horses and our data suggest that 
the cells do not differ in their quality or trilineage potential (8). As 
referenced previously, a study examining large and small volume 
aspirates (50 and 5  ml) did find that ilial aspirates had higher 
proliferation rates in vitro and greater chondrogenic propensity 
(9). Another recent study investigating cell growth rates found 
that there were significantly higher growth rates in aspirates from 
the sternum in middle-aged horses (10). This study concluded 
that there are less viable cells aspirated from equine ilium in 
middle-aged horses. Perhaps cells from the sternum and ilium 
change their growth and multi-lineage propensity over the age 
of the horse, and this change is worthy of further investigation.
Equine MSCs have been used clinically to treat a number of 
tendon injuries, and have been successful (2, 15, 16). Several 
studies have demonstrated MSCs capacity to become tenogenic 
in vitro (6, 19). A major aim of this project was to determine if there 
were differences in BMDMSC’s propensity to become tenogenic 
when acquired from sternum and ilium. BMDMSCs cultured in 
tenogenic media were lifted after 21 days and gene expression was 
quantified for Col I, Scleraxis and Tenascin (Figure 5) (19). There 
were no statistically significant differences between sternum and 
ilium; however, the differences in scleraxis expression between 
sternum and ilium was approaching a significant value (p = 0.08). 
Scleraxis is important as it is a specific marker for tendons and 
ligaments (33). Previous studies have indicated that scleraxis is 
essential in tendon differentiation and force transmission (34). 
Our data illustrate a trend of cells from the sternum to express 
higher levels of scleraxis, potentially indicative of tenogenic 
activity.
Finally, utilizing growth factors to enhance healing has been 
shown to enhance repair of musculoskeletal tissues (21, 35). 
Viral gene therapy vectors have been shown to result in efficient 
enhancement of growth factors in the sites of orthopedic injuries, 
and MSCs offer a unique target. Our data examined BMDMSCs 
FigUre 5 | Tenogenic gene expression of samples from ilium and sternum were not found to be statistically significantly different at 21 days of cell 
culture (n = 9). Relative gene expression: collagen ilium (18.51 ± ST error 9.37) and sternum (3.42 ± ST error 1.93), scleraxis ilium (1.445 ± ST error 1.04) and 
sternum (35.26 ± 16.24), tenascin ilium (5.84 ± ST error 14.38) and sternum (10.46 ± ST error 26.64).
FigUre 4 | cell surface marker antigen expression of passage three Mscs from ilium and sternum (n = 9). Cell surface marker antigen expression was 
not found to be different across aspiration locations. Values in percent flourescence above background for CD11a/18 ilium (9.87 ± ST error 1.73) and sternum 
(6.34 ± ST error 1.08), CD34 ilium (11.29 ± ST error 2.36) and sternum (9.19 ± ST error 1.63), CD44 ilium (71.20 ± ST error 5.50) and sternum (69.46 ± ST error 
3.70), CD90 ilium (74.70 ± ST error 7.16) and sternum (75.34 ± ST error 4.92).
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from sternum and ilium and their viral transduction efficiencies 
quantified by fluorescence of a green protein (GFP). We did not 
find a statistically significant difference in gene transduction 
potential between BMDMSCs derived from sternum or ilium. 
Studies examining equine BMDMSC transduction have used 
sternal or ilium aspirates exclusively, both with transduction suc-
cess (23, 35). Our data are the first to suggest that there is no dif-
ference between aspiration sites in gene transduction efficiencies.
The hypothesis that there would be no significant difference of 
BMDMSCs harvested from sternal and ilial aspiration sites with 
regard to trilineage potential, tenogenesis, cell surface markers, 
and gene therapeutic potential was proven, although a trend for 
increased scleraxis existed for sternal samples. Future studies 
examining cell characteristics when MSCs are placed in  vivo 
will determine if in  vitro results closely correlate with in  situ 
characteristics.
FigUre 6 | Viral transduction of BMDMscs with scaaV2gFP (n = 9). (a) Viral transduction efficiencies of MSCs cultured from ilium (61.81% 
fluorescence ± ST error 5.78) and sternum (70.97%fluorescence ± ST error 8.59) were not found to be different when transduced with scAAV2GFP. (B) Cells from 
sternum and ilium after gene transduction with scAAV2GFP.
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cOnclUsiOn
This study suggests that equine MSCs derived from the sternum 
and the ilium have robust chondrogenic, osteogenic, and teno-
genic capacity. Future studies are needed on the differences in 
levels of scleraxis noted. The cell surface markers are not signifi-
cantly different between aspiration locations, and gene transduc-
tion efficiencies reveal that they are also good candidates for gene 
therapeutic applications. Further in  vivo studies are needed to 
determine actual clinical significance of these data.
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